Seroatlas · Human Serome Atlas

PPIL6

Probable inactive peptidyl-prolyl cis-trans isomerase-like 6

Also known as: bA425D10.6, dJ919F19.1, MGC41939, PPIL6_HUMAN, RSPH12

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8IXY8
Gene: PPIL6
Ensembl: ENSG00000185250
Chromosome: 6
Canonical length: 311 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoli,Vesicles

OverviewNCBI Gene

Predicted to enable RNA polymerase II CTD heptapeptide repeat P3 isomerase activity and RNA polymerase II CTD heptapeptide repeat P6 isomerase activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

311 residues, UniProt reviewed canonical sequence.

>Q8IXY8|PPIL6
     1  MARPQPCGPP HARCGSPSLP ERPLQVKVVG LFSCPNFQIA KSAAENLKNN HPSKFEDPIL
    61  VPLQEFAWHQ YLQEKKRELK NETWEYSSSV ISFVNGQFLG DALDLQKWAH EVWDIVDIKP
   121  SALYDALTED FSAKFLRDTK HDFVFLDICI DSSPIGRLIF ELYCDVCPKT CKNFQVLCTG
   181  KAGFSQRGIR LHYKNSIFHR IVQNGWIQGG DIVYGKGDNG ESIYGPTFED ENFSVPHNKR
   241  GVLGMANKGR HSNGSQFYIT LQATPYLDRK FVAFGQLIEG TEVLKQLELV PTQNERPIHM
   301  CRITDSGDPY A

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PPIL6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 34 nTPM

Expression across tissuesHPA

Tissue

fallopian tube: 34 nTPM
testis: 18 nTPM
choroid plexus: 13 nTPM
thyroid gland: 10 nTPM
epididymis: 8.4 nTPM
retina: 6.9 nTPM

Single-cell type

fallopian tube ciliated cells: 530 nCPM
respiratory ciliated cells: 525 nCPM
late primary spermatocytes: 424 nCPM
epididymal efferent duct ciliated cells: 394 nCPM
endometrial ciliated cells: 378 nCPM
ependymal cells: 369 nCPM

Immune cell

memory B-cell: 1.5 nTPM
basophil: 0.7 nTPM
naive B-cell: 0.5 nTPM
neutrophil: 0.4 nTPM
NK-cell: 0.4 nTPM
plasmacytoid DC: 0.4 nTPM

Brain region

choroid plexus: 23 nTPM
midbrain: 15 nTPM
medulla oblongata: 14 nTPM
spinal cord: 13 nTPM
white matter: 13 nTPM
cerebellum: 9.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.3
gnomAD pLI: 0
gnomAD missense Z: -0.24
DepMap mean gene effect: -0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Cellular components

cytoplasm

Protein domainsUniProt · Pfam · InterPro

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PPIL6 as an antibody target. Whether an autoantibody or antibody against PPIL6 could matter depends on whether native PPIL6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PPIL6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PPIL6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...